Delivery Order SPE2DB22D1202-SPE2DB25FUXM0

Award Date 4/8/25
Potential Completion Date 4/9/25
Potential Value $39K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,798.72, is for the procurement of Ozempic 0.25-0.5 mg/dose pens. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $15,302.30, is for the supply of Ozempic 0.25-0.5 mg/dose pens. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC covers a...
This is a $16,603.86 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for Ozempic 0.25-0.5 mg/dose pens (3 mL) and has a completion date of July 5, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a leading global pharmaceutical distribution company. The contract, valued at $16,717.73, is for the supply of Ozempic 0.25-0.5 mg/dose pens to support military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to AmerisourceBergen Drug Corp by DLA, which...
This is a $10,471.11 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens with a 3 mL volume. The order has an ultimate completion date of January 29, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
This is a $30,077.15 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens with a completion date of March 5, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $75,829.14, is for the delivery of Ozempic 0.25-0.5 mg/dose pens. The contract has an ultimate completion date of March 31, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,079.62, is for the supply of Ozempic 0.25-0.5 mg/dose pens with a 3 ml capacity. The contract has an ultimate completion date of January 30, 2025 and was awarded on January 29, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at...
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,818.73 contract is for the supply of Ozempic 0.25-0.5 mg/dose pens. This order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through December 2026. The contract is not set aside...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $6,843.62, is for the delivery of Ozempic 0.25-0.5 mg/dose pens. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB25FUXM0
    Delivery Order

This is a firm-fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $38,729.27, is for the supply of Ozempic 0.25-0.5 mg/dose pens with a 3 mL capacity. The delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 7/8/25, 2:19 PM